Explore Jobs
Find Specific Jobs
Explore Careers
Explore Professions
Best Companies
Explore Companies
Boehringer Ingelheim history
Boehringer Ingelheim company history timeline
The next milestone for the company was its launch of Actilyse in 1987, as this was the first thrombolytic treatment for acute heart attacks.
In 1991, 9.6 percent of Boehringer Ingelheim's total sales derived from chemicals.
1992: Erich von Baumbach, son-in-law of Albert Boehringer, Jr., becomes CEO.
In 1995, Boehringer Ingelheim’s global R&,D expenditure exceeded 1 billion Deustche Mark (the German currency before the Euro) and a total of 23,277 people were employed.
The new logo involving a logogram and logotype has been valid since November 1997.
In 1998 Boehringer Ingelheim introduced a new organizational structure.
1998: A new organizational structure is established.
In 1999 Boehringer Ingelheim transferred its marketing activities to the food, cosmetics, and chemical industries to Purac Deutschland GmbH, a subsidiary of Dutch Purac Biochem bv, the world's largest producer of lactic acid.
1999: Ben Venue Laboratories in Bedford, Ohio is acquired.
Boehringer bought the rights to market the heartburn reliever Zantac — also known as ranitidine — from Pfizer in 2006.
A year later, another direct descendant of the founder of Boehringer Ingelheim joined the committee, but it was until January 2007 that Christian Boehringer became Chairman.
Drugwatch.com has provided reliable, trusted information about medications, medical devices and general health since 2008.
Starting in 2008, people began filing lawsuits claiming that Spiriva could cause fatal heart problems such as heart attacks, strokes and cardiovascular death.
In 2010, Boehringer Ingelheim had sales worldwide of EU €12.6 billion – the total sales in the UK was £397.5 million.
In 2010, Boehringer Ingelheim reached its 125th anniversary.
Pradaxa (dabigatran), was approved in 2010 as a new type of anticoagulant to prevent clot formation in heart arrhythmia.
In 2011, a division of Boehringer, Ben Venue Laboratories, located in Bedford, Ohio was voluntarily closed after the United States Food and Drug Administration (FDA) found irregularities within the plant.
Before its launch in September 2012, Google had over 50,000 searches for Syrum – showing just how popular Boehringer’s innovative move towards gamification really was.
In 2012, the company paid $64,475 to settle EPA violations regarding mishandled mercury waste and was required to spend hundreds of thousands to develop a qualified hazardous waste facility.
But by the end of 2012, Pradaxa was linked to more than 500 deaths involving hemorrhaging and uncontrolled bleeding.
United States Food and Drug Administration. (2013, March 14). FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes.
The company spent $300 million to upgrade the factory but closed the facility at the end of 2013 after it was unable to return to full-scale manufacturing.
Pradaxa is one of Boehringer’s bestselling products and produced over $1.5 billion in 2013 revenue for the company but many patients have reported serious side effects.
2013 – Failure of Spiriva inhaler lots to meet dose uniformity product specifications which were released for shipment
In March of 2014, Boehringer Ingelheim and Eli Lilly announced that a new diabetes drug that was intended for co-promotion would not be approved by the FDA due to previous cGMP violations at the Boehringer plant in Ingelheim that had not been corrected.
The manufacturer settled more than 4,000 lawsuits in May 2014 for $650 million.
Then, the company sold the United States rights to Sanofi in 2016.
The company had 2017 revenue of nearly $19 billion with products in Animal Health and Prescription Medicine and has an estimated 48,000 employees around the world.
She joined Drugwatch in 2017.
In 2018, the FDA warned that SGLT2 inhibitors including Jardiance, Invokana and Farxiga may contribute to a rare, life-threatening genital infection called Fournier’s gangrene.
In 2018, Boehringer increased its focus in biopharmaceutics with partnerships and acquisitions to access or acquire medications including several oncologics, immunologics, and vaccines.
In 2019’s fifth edition of The Corporate Reputation of Pharma – from the Perspective of Respiratory-Conditions Patient Groups, Boehringer ranked first out of 13 companies for corporate reputation.
Headquartered in Ingelheim, Germany, Boehringer did 46 percent of its sales in the Americas in 2019, the largest geographical sector for the company.
The company spent about $4.1 billion in research and development in 2019.
In 2019, companies began recalling Zantac after NDMA, a carcinogenic chemical, was found in batches of the drug.
Reuters. (2020, November 10). Boehringer to settle thousands of cases over Pradaxa blood thinner bleeding risk.
In response to the COVID-19 pandemic, Boehringer stepped up its research and development efforts to study new treatments and repurpose existing products to fight the virus in 2020.
Boehringer Ingelheim. (2020). Retrieved from https://www.boehringer-ingelheim.com/press-release/fight-against-covid-19-pandemic-shapes-global-business-activities
As of Feb 17, 2021, there were still 1,012 pending claims in the incretin mimetic MDL.
© 2022 Drugwatch.com Privacy Policy / Advertising Disclosure / Do Not Sell My Info
According to Evaluate Pharma’s Report, “World Preview 2019, Outlook to 2022,” Boehringer ranks 20th for prescription drug sales in the United States, 15th for drug sales in Europe and 17th in Japan. It is projected to be 19th worldwide in 2022.
Rate how well Boehringer Ingelheim lives up to its initial vision.
Boehringer Ingelheim jobs
Do you work at Boehringer Ingelheim?
Does Boehringer Ingelheim communicate its history to new hires?
Boehringer Ingelheim competitors
| Company Name | Founded Date | Revenue | Employee Size | Job Openings |
|---|---|---|---|---|
| URL Pharma | 1946 | $38.0M | 211 | - |
| Alvogen | 2008 | $1.1B | 2,800 | - |
| Teva Pharmaceuticals | 1901 | $14.9B | 4,999 | 115 |
| Novartis | 1996 | $49.9B | 110,000 | 151 |
| AstraZeneca | 1999 | $25.9B | 76,100 | 518 |
| Eli Lilly and Company | 1876 | $28.5B | 33,625 | 891 |
| Merial Limited | 1981 | $2.7B | 6,900 | - |
| Merck | 1891 | $59.3B | 74,000 | 1,574 |
| Bristol-Myers Squibb | 1887 | $46.2B | 30,000 | 820 |
| Janssen | 1953 | $601.4M | 1,500 | - |
Boehringer Ingelheim history FAQs
Zippia gives an in-depth look into the details of Boehringer Ingelheim, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Boehringer Ingelheim. The employee data is based on information from people who have self-reported their past or current employments at Boehringer Ingelheim. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Boehringer Ingelheim. The data presented on this page does not represent the view of Boehringer Ingelheim and its employees or that of Zippia.
Boehringer Ingelheim may also be known as or be related to Boehringer Ingelheim, Boehringer Ingelheim Corp, Boehringer Ingelheim Corporation and C. H. Boehringer Sohn AG & Co. KG.